drugset / Trial / NCT05862402

Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital

NCT05862402

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The patients who infected with Carbapenem resistant Klebsiella pneumoniae were high mortality rate. Appropriate antibiotics therapy adjusted by Pharmacokinetic/Pharmacodynamic plays an important role in determining outcomes in Critically ill patients. Consequently, standard antibiotics dose may not be adequate to achieve pharmacokinetic/pharmacodynamic target in Critically ill patients. The purpose of this study is to compare the clinical outcomes between the critically ill patients who received antibiotics dose adjusted by pharmacokinetic/pharmacodynamic using Monte Carlo simulation and historical critically ill patients who received antibiotics from standard practice.

Timeline

Start
2023-05-07
Primary completion
2024-05-31
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amikacin Small molecule
Subject Ceftazidime-avibactam Other / unclassified
Subject Colistin Other / unclassified
Subject Gentamicin Small molecule
Subject IMIPENEM ANHYDROUS Small molecule
Subject Meropenem Small molecule
Subject Tigecycline Small molecule

Indications